Skip to main content
Erschienen in: Rheumatology International 10/2012

01.10.2012 | Original Article

Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population

verfasst von: Jinwei Chen, Lixiao Chen, Ni Mao, Yiming Liu

Erschienen in: Rheumatology International | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

To evaluate whether the multidrug resistance gene 1 (MDR1) exon 26 polymorphisms are associated with the refractory rheumatoid arthritis (RRA). The study was carried out on two hundred and twenty-three patients with RA treated and one hundred and three normal controls. The RA treated were divided into two groups according the response to disease-modifying antirheumatic drugs (DMARDs). There were 108 patients in the effective group and 115 patients in the ineffective group. Genotypes of the C3435T polymorphism were determined by polymerase chain reaction followed by restriction digestion (PCR–RFLP). There were significant differences in the genotype frequency and allele frequency among three groups. Compared to responders and controls, the nonresponders carried more CC genotype (χ2 = 5.306, P = 0.021; χ2 = 7.810, P = 0.005) and more C allele (χ2 = 6.601, P = 0.010; χ2 = 12.172, P = 0.000). But, there were no statistically significant differences in genotype nor allele frequency between RA and healthy controls. The results from our study suggest that the C3435T MDR1 gene polymorphism may not be related with the RA susceptibility, but may influence the efficacy of RA therapy with DMARDs, and the 3435CC genotype may be related with RRA.
Literatur
1.
Zurück zum Zitat Liu F, Wang C, Zhang Q, Li J, Zhang Y (2002) Establishment of multidrug resistance cell line C6/adr and reversal of drug resistance. Clin Med J (Engl) 115(2):238 Liu F, Wang C, Zhang Q, Li J, Zhang Y (2002) Establishment of multidrug resistance cell line C6/adr and reversal of drug resistance. Clin Med J (Engl) 115(2):238
2.
Zurück zum Zitat Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62(11):933–937 Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62(11):933–937
3.
Zurück zum Zitat Marchetti S, Mazzanti R, Beijnen JH, Jan Schellensa HM (2007) Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927–941 Marchetti S, Mazzanti R, Beijnen JH, Jan Schellensa HM (2007) Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927–941
4.
Zurück zum Zitat Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67(3):380–388PubMedCrossRef Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67(3):380–388PubMedCrossRef
5.
Zurück zum Zitat Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496–503PubMed Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496–503PubMed
6.
Zurück zum Zitat Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herezynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933–937 Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herezynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933–937
7.
Zurück zum Zitat Mc Carthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18(5):505CrossRef Mc Carthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18(5):505CrossRef
8.
Zurück zum Zitat Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics 11(3):217–221 Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics 11(3):217–221
9.
Zurück zum Zitat Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H et al (2000) Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30–39 Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H et al (2000) Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30–39
10.
Zurück zum Zitat Rahgu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-Glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258–1264 Rahgu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-Glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258–1264
11.
Zurück zum Zitat Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et al (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2, IL-4, and interferon-gamma in normal human T lymphocytes. Blood (88):1747–1754 Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et al (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2, IL-4, and interferon-gamma in normal human T lymphocytes. Blood (88):1747–1754
12.
Zurück zum Zitat Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef
13.
Zurück zum Zitat Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMed Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMed
14.
Zurück zum Zitat Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef
Metadaten
Titel
Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population
verfasst von
Jinwei Chen
Lixiao Chen
Ni Mao
Yiming Liu
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 10/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2088-3

Weitere Artikel der Ausgabe 10/2012

Rheumatology International 10/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.